Difference between revisions of "Epidermal growth factor receptor inhibitors"

Jump to navigation Jump to search
+TKI
m (w)
(+TKI)
Line 2: Line 2:


==Drugs==
==Drugs==
*Gefitinib (Iressa).<ref name=pmid20855837/>  
*[[Gefitinib]] (Iressa).<ref name=pmid20855837/>  
*Erlotinib (Tarceva)).<ref name=pmid20855837>{{cite journal |author=Sun Y, Ren Y, Fang Z, ''et al.'' |title=Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases |journal=J. Clin. Oncol. |volume=28 |issue=30 |pages=4616–20 |year=2010 |month=October |pmid=20855837 |doi=10.1200/JCO.2010.29.6038 |url=}}</ref>
*[[Erlotinib]] (Tarceva)).<ref name=pmid20855837>{{cite journal |author=Sun Y, Ren Y, Fang Z, ''et al.'' |title=Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases |journal=J. Clin. Oncol. |volume=28 |issue=30 |pages=4616–20 |year=2010 |month=October |pmid=20855837 |doi=10.1200/JCO.2010.29.6038 |url=}}</ref>
 
Note:
*Both ''gefitinib'' and ''erlotinib'' are also classified as ''tyrosine kinase inhibitors'' (TKI).


==Use==
==Use==
48,830

edits

Navigation menu